Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Multicenter randomized phase ll study of XELOX plus bevacizumab or XELIRI plusbevacizumab as first-line chemotherapy for metastatic or recurrent colorectal cancer

ABSTRACT: Interventions: XELOX plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Oxaliplatin 130mg/m2 day1 Capecitabin 2,000mg/m2/day day1-15 XELIRI plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Irinotecan 200mg/m2 day1 Capecitabin 1,600mg/m2/day day1-15 Primary outcome(s): ORR; Overall response rate Study Design: Parallel Randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2622964 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Phase II study of XELIRI and bevacizumab as second-line therapy in patients with metastatic colorectal cancer

Project description:Interventions: XELIRI plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Irinotecan 160mg/m2 day1 Capecitabin 1,600mg/m2/day day1-15 Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

| 2624073 | ecrin-mdr-crc

Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine, irinotecan plus bevacizmab for metastatic colorectal cancer

Project description:Interventions: XELOX plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 Oxaliplatin 130mg/m2 day1 Capecitabin 2000mg/m2/day day1-15 Primary outcome(s): ORR;Over response rate Study Design: Single arm Non-randomized

| 2626922 | ecrin-mdr-crc

Phase II study of XELOX plus bevacizumab as second-line chemotherapy prior oral fluoropyrimidine,oxaliplatin plus bevacizumab for metastatic colorectal cancer

Project description:Interventions: XELOX plus bevacizumab therapy Bevacizumab 7.5mg/kg day1 irinotecan 130mg/m2 day1 Capecitabin 1600mg/m2/day day1-15 Primary outcome(s): ORR;Overall response rate Study Design: Single arm Non-randomized

| 2627045 | ecrin-mdr-crc

Phase II study of XELIRI and High-dose bevacizumab as second-line therapy in patients with metastatic colorectal cancer

Project description:Interventions: XELIRI plus bevacizumab therapy Bevacizumab 10mg/kg day1 Irinotecan 150mg/m2 day1 Capecitabin 2,000mg/m2/day day1-8 Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

| 2623833 | ecrin-mdr-crc

Assessment of clinical efficacy and safety in capecitabine plus intermittent oxaliplatin (intermittent CapeOx)together with Bevacizumab as the first-line therapy for patients with advanced colorectal cancer; multicenter phase II trial

Project description:Interventions: capecitabine plus intermittent oxaliplatin (CapeOx) in combination with Bevacizumab: (CapeOx + Bevacizumab)x5 cycles followed by (Capecitabine + Bevacizumab )x5 cycles, followed by (CapeOx + Bevacizumab)x5 cycles are administered until progression. [CapeOx + Bevacizumab] Capecitabine: 2000mg/m2/day p.o. (day1-15) Oxaliplatin: 130mg/m2 i.v. (day1) Bevacizumab: 7.5mg/kg i.v. (day1) to be repeated every 3 weeks [Capecitabine + Bevacizumab] Capecitabine: 2000mg/m2/day p.o. (day1-15) Bevacizumab: 7.5mg/kg i.v. (day1) to be repeated every 3 weeks Primary outcome(s): progression free survival (PFS) Study Design: Single arm Non-randomized

| 2621169 | ecrin-mdr-crc

Phase II study of chemotherapy with Capecitabine/Bevacizumab in elderly patients with advanced and recurrent colorectal cancer

Project description:Interventions: Capecitabine plus bevacizumab therapy Capecitabine:2,000mg/m2 twice daily (orally, day1 after dinner:day8 after breakfast) Bevacizumab:7.5mg/kg day 1 The treatment is repeated every three weeks until disease progression or severe toxicity. Primary outcome(s): Progression Free Survival Study Design: Single arm Non-randomized

| 2625591 | ecrin-mdr-crc

Clinical efficacy and biomarker assessment of Capecitabine plus oxaliplatin (XELOX) in combination with Bevacizumab as second-line therapy in patients with advanced or recurrent colorectal cancer after failure to irinotecan. Multi-center phase II Study.

Project description:Interventions: Capecitabine plus oxaliplatin (XELOX) in combination with Bevacizumab. Capecitabine:2000mg/m2/day p.o.(day1-15) Oxaliplatin:130mg/m2 i.v.(day1) Bevacizumab:7.5mg/kg i.v.(day1) to be repeated every 3 weeks Primary outcome(s): 6-month Progression free survival rate Study Design: Single arm Non-randomized

| 2620624 | ecrin-mdr-crc

A randomized phase III study of oxaliplatin based chemotherapy versus combination chemotherapy of TS-1,irinotecan and bevacizumab as first line therapy for unresectable or recurrent colorectal cancer

Project description:Interventions: arm A-1:mFOLFOX6+Bevacizumab Bevacizumab 5mg/kg/bi-week L-OHP 85mg/m2/bi-week l-LV 200mg/m2/bi-week 5-FU/bolus 400mg/m2/bi-week 5-FU/infusional 2,400mg/m2/bi-week arm A-2: CapeOX+Bevacizumab Bevacizumab 7.5mg/kg/tri-week L-OHP 130mg/m2/tri-week Capecitabine 1200-2100mg/twice/day(day 1-15) arm B-1:TS-1/CPT-11+Bevacizumab(SIRB) Bevacizumab 7.5mg/kg/tri-week CPT-11 150mg/m2/tri-week S-1 40-60mg/twice/day(day1-15)/tri-week arm B-2:TS-1/CPT-11+Bevacizumab(IRIS/BV) Bevacizumab 5mg/kg/(day1and15)/4-weeks CPT-11 100mg/m2/(day1and15)/4-weeks S-1 40-60mg/twice/day(day1-15)/4weeks Primary outcome(s): Progression free survival(PFS) Study Design: Parallel Randomized

| 2623247 | ecrin-mdr-crc

A phase II Study of Useful therapeutic strategy for metastatic Colorectal Cancer to Evaluate Oxaliplatin Stop and Go in SOX+Bmab

Project description:Interventions: TS-1 80mg/m2/day (day1-14) and Oxaliplatin 130mg/m2 (day1) and Bevacizumab 7.5mg/kg (day1) every 21 days for 4 courses followed by TS-1 80mg/m2/day (day1-14) and Bevacizumab 7.5mg/kg (day1) every 21 days for 8 courses. And next, administer until PD the same SOX+Bmab regimen. Primary outcome(s): Progression-free Survival Study Design: Single arm Non-randomized

| 2622829 | ecrin-mdr-crc

Phase II study of S-1+CPT-11+Bevacizumab as second-line therapy in metastatic colorectal cancer which has prior therapy of S-1+L-OHP+Bevacizumab

Project description:Interventions: Bevacizumab 7.5mg/kg/tri-week CPT-11 150mg/m2/tri-week S-1 40-60mg/twice/day(day1-15)/tri-week Primary outcome(s): Progression-free survival Study Design: Single arm Non-randomized

| 2630432 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data